デフォルト表紙
市場調査レポート
商品コード
1321252

オリゴヌクレオチド治療薬の世界市場

Oligonucleotide Therapeutics

出版日: | 発行: Global Industry Analysts, Inc. | ページ情報: 英文 193 Pages | 納期: 即日から翌営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=152.52円
オリゴヌクレオチド治療薬の世界市場
出版日: 2023年08月04日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 193 Pages
納期: 即日から翌営業日
● ご注意事項
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 目次
概要

オリゴヌクレオチド治療薬の世界市場は2030年までに44億米ドルに達する

COVID-19後のビジネス環境が変化する中、2022年に23億米ドルと推計されたオリゴヌクレオチド治療薬の世界市場規模は、2030年には44億米ドルに達すると予測され、2022年から2030年にかけてCAGR 8.7%で成長すると予測されています。アンチセンス/RNAIオリゴヌクレオチドは、本レポートで分析されているセグメントの1つであり、CAGR 9.4%を記録し、分析期間終了時には36億米ドルに達すると予測されています。現在進行中のパンデミック後の回復を考慮し、その他の技術分野の成長は今後8年間のCAGRを6.4%に修正しました。

米国市場は6億8,910万米ドル、中国はCAGR7.9%で成長すると予測

米国のオリゴヌクレオチド治療薬市場は、2022年に6億8,910万米ドルと推定されます。世界第2位の経済大国である中国は、2022年から2030年までの分析期間においてCAGR 7.9%で推移し、2030年までに7億4,490万米ドルの市場規模に達すると予測されています。その他の注目すべき地理的市場としては、日本とカナダがあり、2022年から2030年にかけてそれぞれ8.1%と7%の成長が予測されています。欧州では、ドイツがCAGR約7%で成長すると予測されています。

調査対象企業の例

  • Arrowhead Pharmaceuticals, Inc.
  • GlaxoSmithKline PLC
  • Ionis Pharmaceuticals, Inc.
  • miRagen Therapeutics, Inc.
  • Sarepta Therapeutics Inc.

目次

第1章 調査手法

第2章 エグゼクティブサマリー

  • 市場概要
  • 主要企業
  • 市場動向と促進要因
  • 世界市場の見通し

第3章 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • その他欧州
  • アジア太平洋
  • 世界のその他の地域

第4章 競合

目次
Product Code: MCP13701

What`s New for 2023?

»Special coverage on Russia-Ukraine war; global inflation; easing of "zero-Covid" policy in China and its `bumpy` reopening; supply chain disruptions, global trade tensions; and risk of recession.

»Global competitiveness and key competitor percentage market shares

» Market presence across multiple geographies - Strong/Active/Niche/Trivial

»Online interactive peer-to-peer collaborative bespoke updates

»Access to our digital archives and MarketGlass Research Platform

»Complimentary updates for one year

Looking Ahead to 2023

The global economy is at a critical crossroads with a number of interlocking challenges and crises running in parallel. The uncertainty around how Russia`s war on Ukraine will play out this year and the war`s role in creating global instability means that the trouble on the inflation front is not over yet. Food and fuel inflation will remain a persistent economic problem. Higher retail inflation will impact consumer confidence and spending. As governments combat inflation by raising interest rates, new job creation will slowdown and impact economic activity and growth. Lower capital expenditure is in the offing as companies go slow on investments, held back by inflation worries and weaker demand. With slower growth and high inflation, developed markets seem primed to enter into a recession. Fears of new COVID outbreaks and China's already uncertain post-pandemic path poses a real risk of the world experiencing more acute supply chain pain and manufacturing disruptions this year. Volatile financial markets, growing trade tensions, stricter regulatory environment and pressure to mainstream climate change into economic decisions will compound the complexity of challenges faced. Year 2023 is expected to be tough year for most markets, investors and consumers. Nevertheless, there is always opportunity for businesses and their leaders who can chart a path forward with resilience and adaptability.

Global Oligonucleotide Therapeutics Market to Reach $4.4 Billion by 2030

In the changed post COVID-19 business landscape, the global market for Oligonucleotide Therapeutics estimated at US$2.3 Billion in the year 2022, is projected to reach a revised size of US$4.4 Billion by 2030, growing at aCAGR of 8.7% over the period 2022-2030. Antisense / RNAI Oligonucleotides, one of the segments analyzed in the report, is projected to record 9.4% CAGR and reach US$3.6 Billion by the end of the analysis period. Taking into account the ongoing post pandemic recovery, growth in the Other Technologies segment is readjusted to a revised 6.4% CAGR for the next 8-year period.

The U.S. Market is Estimated at $689.1 Million, While China is Forecast to Grow at 7.9% CAGR

The Oligonucleotide Therapeutics market in the U.S. is estimated at US$689.1 Million in the year 2022. China, the world`s second largest economy, is forecast to reach a projected market size of US$744.9 Million by the year 2030 trailing a CAGR of 7.9% over the analysis period 2022 to 2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 8.1% and 7% respectively over the 2022-2030 period. Within Europe, Germany is forecast to grow at approximately 7% CAGR.

Select Competitors (Total 44 Featured) -

  • Arrowhead Pharmaceuticals, Inc.
  • GlaxoSmithKline PLC
  • Ionis Pharmaceuticals, Inc.
  • miRagen Therapeutics, Inc.
  • Sarepta Therapeutics Inc.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Oligonucleotide Therapeutics - Global Key Competitors Percentage Market Share in 2022 (E)
    • Impact of Covid-19 and a Looming Global Recession
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2022 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Recent Past, Current & Future Analysis for Neurological Disorders by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR
    • TABLE 2: World Historic Review for Neurological Disorders by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 3: World 16-Year Perspective for Neurological Disorders by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2023 & 2030
    • TABLE 4: World Recent Past, Current & Future Analysis for Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR
    • TABLE 5: World Historic Review for Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 6: World 16-Year Perspective for Cancer by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2023 & 2030
    • TABLE 7: World Recent Past, Current & Future Analysis for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR
    • TABLE 8: World Historic Review for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 9: World 16-Year Perspective for Other Applications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2023 & 2030
    • TABLE 10: World Recent Past, Current & Future Analysis for Other Technologies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR
    • TABLE 11: World Historic Review for Other Technologies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 12: World 16-Year Perspective for Other Technologies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2023 & 2030
    • TABLE 13: World Oligonucleotide Therapeutics Market Analysis of Annual Sales in US$ Thousand for Years 2014 through 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Oligonucleotide Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Oligonucleotide Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 16: World 16-Year Perspective for Oligonucleotide Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2014, 2023 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Antisense / RNAI Oligonucleotides by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Antisense / RNAI Oligonucleotides by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 19: World 16-Year Perspective for Antisense / RNAI Oligonucleotides by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2023 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Oligonucleotide Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2023 (E)
    • TABLE 20: USA Recent Past, Current & Future Analysis for Oligonucleotide Therapeutics by Application - Neurological Disorders, Cancer and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 21: USA Historic Review for Oligonucleotide Therapeutics by Application - Neurological Disorders, Cancer and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 22: USA 16-Year Perspective for Oligonucleotide Therapeutics by Application - Percentage Breakdown of Value Sales for Neurological Disorders, Cancer and Other Applications for the Years 2014, 2023 & 2030
    • TABLE 23: USA Recent Past, Current & Future Analysis for Oligonucleotide Therapeutics by Technology - Antisense / RNAI Oligonucleotides and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 24: USA Historic Review for Oligonucleotide Therapeutics by Technology - Antisense / RNAI Oligonucleotides and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 25: USA 16-Year Perspective for Oligonucleotide Therapeutics by Technology - Percentage Breakdown of Value Sales for Antisense / RNAI Oligonucleotides and Other Technologies for the Years 2014, 2023 & 2030
  • CANADA
    • TABLE 26: Canada Recent Past, Current & Future Analysis for Oligonucleotide Therapeutics by Application - Neurological Disorders, Cancer and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 27: Canada Historic Review for Oligonucleotide Therapeutics by Application - Neurological Disorders, Cancer and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 28: Canada 16-Year Perspective for Oligonucleotide Therapeutics by Application - Percentage Breakdown of Value Sales for Neurological Disorders, Cancer and Other Applications for the Years 2014, 2023 & 2030
    • TABLE 29: Canada Recent Past, Current & Future Analysis for Oligonucleotide Therapeutics by Technology - Antisense / RNAI Oligonucleotides and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 30: Canada Historic Review for Oligonucleotide Therapeutics by Technology - Antisense / RNAI Oligonucleotides and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 31: Canada 16-Year Perspective for Oligonucleotide Therapeutics by Technology - Percentage Breakdown of Value Sales for Antisense / RNAI Oligonucleotides and Other Technologies for the Years 2014, 2023 & 2030
  • JAPAN
    • Oligonucleotide Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2023 (E)
    • TABLE 32: Japan Recent Past, Current & Future Analysis for Oligonucleotide Therapeutics by Application - Neurological Disorders, Cancer and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 33: Japan Historic Review for Oligonucleotide Therapeutics by Application - Neurological Disorders, Cancer and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 34: Japan 16-Year Perspective for Oligonucleotide Therapeutics by Application - Percentage Breakdown of Value Sales for Neurological Disorders, Cancer and Other Applications for the Years 2014, 2023 & 2030
    • TABLE 35: Japan Recent Past, Current & Future Analysis for Oligonucleotide Therapeutics by Technology - Antisense / RNAI Oligonucleotides and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 36: Japan Historic Review for Oligonucleotide Therapeutics by Technology - Antisense / RNAI Oligonucleotides and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 37: Japan 16-Year Perspective for Oligonucleotide Therapeutics by Technology - Percentage Breakdown of Value Sales for Antisense / RNAI Oligonucleotides and Other Technologies for the Years 2014, 2023 & 2030
  • CHINA
    • Oligonucleotide Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2023 (E)
    • TABLE 38: China Recent Past, Current & Future Analysis for Oligonucleotide Therapeutics by Application - Neurological Disorders, Cancer and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 39: China Historic Review for Oligonucleotide Therapeutics by Application - Neurological Disorders, Cancer and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 40: China 16-Year Perspective for Oligonucleotide Therapeutics by Application - Percentage Breakdown of Value Sales for Neurological Disorders, Cancer and Other Applications for the Years 2014, 2023 & 2030
    • TABLE 41: China Recent Past, Current & Future Analysis for Oligonucleotide Therapeutics by Technology - Antisense / RNAI Oligonucleotides and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 42: China Historic Review for Oligonucleotide Therapeutics by Technology - Antisense / RNAI Oligonucleotides and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 43: China 16-Year Perspective for Oligonucleotide Therapeutics by Technology - Percentage Breakdown of Value Sales for Antisense / RNAI Oligonucleotides and Other Technologies for the Years 2014, 2023 & 2030
  • EUROPE
    • Oligonucleotide Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2023 (E)
    • TABLE 44: Europe Recent Past, Current & Future Analysis for Oligonucleotide Therapeutics by Application - Neurological Disorders, Cancer and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 45: Europe Historic Review for Oligonucleotide Therapeutics by Application - Neurological Disorders, Cancer and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 46: Europe 16-Year Perspective for Oligonucleotide Therapeutics by Application - Percentage Breakdown of Value Sales for Neurological Disorders, Cancer and Other Applications for the Years 2014, 2023 & 2030
    • TABLE 47: Europe Recent Past, Current & Future Analysis for Oligonucleotide Therapeutics by Technology - Antisense / RNAI Oligonucleotides and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 48: Europe Historic Review for Oligonucleotide Therapeutics by Technology - Antisense / RNAI Oligonucleotides and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 49: Europe 16-Year Perspective for Oligonucleotide Therapeutics by Technology - Percentage Breakdown of Value Sales for Antisense / RNAI Oligonucleotides and Other Technologies for the Years 2014, 2023 & 2030
    • TABLE 50: Europe Recent Past, Current & Future Analysis for Oligonucleotide Therapeutics by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR
    • TABLE 51: Europe Historic Review for Oligonucleotide Therapeutics by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 52: Europe 16-Year Perspective for Oligonucleotide Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2014, 2023 & 2030
  • FRANCE
    • Oligonucleotide Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2023 (E)
    • TABLE 53: France Recent Past, Current & Future Analysis for Oligonucleotide Therapeutics by Application - Neurological Disorders, Cancer and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 54: France Historic Review for Oligonucleotide Therapeutics by Application - Neurological Disorders, Cancer and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 55: France 16-Year Perspective for Oligonucleotide Therapeutics by Application - Percentage Breakdown of Value Sales for Neurological Disorders, Cancer and Other Applications for the Years 2014, 2023 & 2030
    • TABLE 56: France Recent Past, Current & Future Analysis for Oligonucleotide Therapeutics by Technology - Antisense / RNAI Oligonucleotides and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 57: France Historic Review for Oligonucleotide Therapeutics by Technology - Antisense / RNAI Oligonucleotides and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 58: France 16-Year Perspective for Oligonucleotide Therapeutics by Technology - Percentage Breakdown of Value Sales for Antisense / RNAI Oligonucleotides and Other Technologies for the Years 2014, 2023 & 2030
  • GERMANY
    • Oligonucleotide Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2023 (E)
    • TABLE 59: Germany Recent Past, Current & Future Analysis for Oligonucleotide Therapeutics by Application - Neurological Disorders, Cancer and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 60: Germany Historic Review for Oligonucleotide Therapeutics by Application - Neurological Disorders, Cancer and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 61: Germany 16-Year Perspective for Oligonucleotide Therapeutics by Application - Percentage Breakdown of Value Sales for Neurological Disorders, Cancer and Other Applications for the Years 2014, 2023 & 2030
    • TABLE 62: Germany Recent Past, Current & Future Analysis for Oligonucleotide Therapeutics by Technology - Antisense / RNAI Oligonucleotides and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 63: Germany Historic Review for Oligonucleotide Therapeutics by Technology - Antisense / RNAI Oligonucleotides and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 64: Germany 16-Year Perspective for Oligonucleotide Therapeutics by Technology - Percentage Breakdown of Value Sales for Antisense / RNAI Oligonucleotides and Other Technologies for the Years 2014, 2023 & 2030
  • ITALY
    • TABLE 65: Italy Recent Past, Current & Future Analysis for Oligonucleotide Therapeutics by Application - Neurological Disorders, Cancer and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 66: Italy Historic Review for Oligonucleotide Therapeutics by Application - Neurological Disorders, Cancer and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 67: Italy 16-Year Perspective for Oligonucleotide Therapeutics by Application - Percentage Breakdown of Value Sales for Neurological Disorders, Cancer and Other Applications for the Years 2014, 2023 & 2030
    • TABLE 68: Italy Recent Past, Current & Future Analysis for Oligonucleotide Therapeutics by Technology - Antisense / RNAI Oligonucleotides and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 69: Italy Historic Review for Oligonucleotide Therapeutics by Technology - Antisense / RNAI Oligonucleotides and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 70: Italy 16-Year Perspective for Oligonucleotide Therapeutics by Technology - Percentage Breakdown of Value Sales for Antisense / RNAI Oligonucleotides and Other Technologies for the Years 2014, 2023 & 2030
  • UNITED KINGDOM
    • Oligonucleotide Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2023 (E)
    • TABLE 71: UK Recent Past, Current & Future Analysis for Oligonucleotide Therapeutics by Application - Neurological Disorders, Cancer and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 72: UK Historic Review for Oligonucleotide Therapeutics by Application - Neurological Disorders, Cancer and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 73: UK 16-Year Perspective for Oligonucleotide Therapeutics by Application - Percentage Breakdown of Value Sales for Neurological Disorders, Cancer and Other Applications for the Years 2014, 2023 & 2030
    • TABLE 74: UK Recent Past, Current & Future Analysis for Oligonucleotide Therapeutics by Technology - Antisense / RNAI Oligonucleotides and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 75: UK Historic Review for Oligonucleotide Therapeutics by Technology - Antisense / RNAI Oligonucleotides and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 76: UK 16-Year Perspective for Oligonucleotide Therapeutics by Technology - Percentage Breakdown of Value Sales for Antisense / RNAI Oligonucleotides and Other Technologies for the Years 2014, 2023 & 2030
  • REST OF EUROPE
    • TABLE 77: Rest of Europe Recent Past, Current & Future Analysis for Oligonucleotide Therapeutics by Application - Neurological Disorders, Cancer and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 78: Rest of Europe Historic Review for Oligonucleotide Therapeutics by Application - Neurological Disorders, Cancer and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 79: Rest of Europe 16-Year Perspective for Oligonucleotide Therapeutics by Application - Percentage Breakdown of Value Sales for Neurological Disorders, Cancer and Other Applications for the Years 2014, 2023 & 2030
    • TABLE 80: Rest of Europe Recent Past, Current & Future Analysis for Oligonucleotide Therapeutics by Technology - Antisense / RNAI Oligonucleotides and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 81: Rest of Europe Historic Review for Oligonucleotide Therapeutics by Technology - Antisense / RNAI Oligonucleotides and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 82: Rest of Europe 16-Year Perspective for Oligonucleotide Therapeutics by Technology - Percentage Breakdown of Value Sales for Antisense / RNAI Oligonucleotides and Other Technologies for the Years 2014, 2023 & 2030
  • ASIA-PACIFIC
    • Oligonucleotide Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2023 (E)
    • TABLE 83: Asia-Pacific Recent Past, Current & Future Analysis for Oligonucleotide Therapeutics by Application - Neurological Disorders, Cancer and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 84: Asia-Pacific Historic Review for Oligonucleotide Therapeutics by Application - Neurological Disorders, Cancer and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 85: Asia-Pacific 16-Year Perspective for Oligonucleotide Therapeutics by Application - Percentage Breakdown of Value Sales for Neurological Disorders, Cancer and Other Applications for the Years 2014, 2023 & 2030
    • TABLE 86: Asia-Pacific Recent Past, Current & Future Analysis for Oligonucleotide Therapeutics by Technology - Antisense / RNAI Oligonucleotides and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 87: Asia-Pacific Historic Review for Oligonucleotide Therapeutics by Technology - Antisense / RNAI Oligonucleotides and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 88: Asia-Pacific 16-Year Perspective for Oligonucleotide Therapeutics by Technology - Percentage Breakdown of Value Sales for Antisense / RNAI Oligonucleotides and Other Technologies for the Years 2014, 2023 & 2030
  • REST OF WORLD
    • TABLE 89: Rest of World Recent Past, Current & Future Analysis for Oligonucleotide Therapeutics by Application - Neurological Disorders, Cancer and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 90: Rest of World Historic Review for Oligonucleotide Therapeutics by Application - Neurological Disorders, Cancer and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 91: Rest of World 16-Year Perspective for Oligonucleotide Therapeutics by Application - Percentage Breakdown of Value Sales for Neurological Disorders, Cancer and Other Applications for the Years 2014, 2023 & 2030
    • TABLE 92: Rest of World Recent Past, Current & Future Analysis for Oligonucleotide Therapeutics by Technology - Antisense / RNAI Oligonucleotides and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 93: Rest of World Historic Review for Oligonucleotide Therapeutics by Technology - Antisense / RNAI Oligonucleotides and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 94: Rest of World 16-Year Perspective for Oligonucleotide Therapeutics by Technology - Percentage Breakdown of Value Sales for Antisense / RNAI Oligonucleotides and Other Technologies for the Years 2014, 2023 & 2030

IV. COMPETITION